glofitamab,Obinutuzumab 
roche
['dlbcl', 'glofitamab', 'car-t', 'lymphoma', 'pivotal']
glofitamab (cd20xcd3 bispecific mab) shows durable responses in r/r dlbcl in a pivotal phase ii trial. 33% had prior car-t therapy #asco22 #lymphoma #dlbcl 
Assist-Prof of Med, @MayoClinic FL, #ASCOTEC, ASCO AMEC. #Lymphoma #PTCL #CTCL #histiocyticDiseases #ClinicalResearch ?????? ????? ?? ?????? #???????